Ory Slonim - Teva Pharmaceutical Independent Director
| TEVA Stock | ILA 4,933 48.00 0.98% |
Director
Mr. Ory Slonim serves as Director at Teva Pharmaceutical Industries Limited since 2008. He is a member of the Audit committee, Vice Chairman of the Corporationrationrate Governance and Nominating committees and Chairman of the Corporationrationrate Responsibility. His work experience includes the following roles Statutory Independent Director at the Company, Attorney, Director and Chairman of the audit committee at U. Dori Group Ltd., Director at Oil Refineries Ltd., Vice Chairman of Harel Insurance Investments and Financial Services Ltd., Vice Chairman of the Board of Migdal Insurance and Financial Holdings Ltd., Chairman of the Variety ClubIsrael, Chairman of the Ethics Tribunal of the Israeli Press Council and Lecturer at Tel Aviv University . Mr. Slonim received the Presidential Volunteer Medal in 1992 and the Presidential Medal of Distinction in 2012. He holds a LLB degree from The Hebrew University of Jerusalem. since 2008.
| Age | 73 |
| Tenure | 16 years |
| Phone | (972) 3 914 8213 |
| Web | www.tevapharm.com |
Teva Pharmaceutical Management Efficiency
The company has return on total asset (ROA) of 0.0363 % which means that it generated a profit of $0.0363 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2414) %, meaning that it generated substantial loss on money invested by shareholders. Teva Pharmaceutical's management efficiency ratios could be used to measure how well Teva Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Joshua Rosensweig | Bezeq Israeli Telecommunication | 63 | |
| Yuli Tamir | Elbit Systems | 65 | |
| Ilan Flato | Tower Semiconductor | 61 | |
| Dana Gross | Tower Semiconductor | 51 | |
| David Granot | Bezeq Israeli Telecommunication | 71 | |
| Dalia Rabin | Elbit Systems | 66 | |
| Edith Lusky | Bezeq Israeli Telecommunication | 66 | |
| Ytzhak Edelman | Bezeq Israeli Telecommunication | 64 | |
| Yigal Neeman | Elbit Systems | 73 | |
| Efraim Sadka | Bank Leumi Le Israel | 68 | |
| Ilan Biran | Bezeq Israeli Telecommunication | 70 | |
| Mordechai Keret | Bezeq Israeli Telecommunication | 60 | |
| Amnon LipkinShahak | El Al Israel | 68 | |
| Eliyahu Defes | El Al Israel | 61 | |
| Eldad Moshe | Bezeq Israeli Telecommunication | 50 | |
| Yael Karni | El Al Israel | 47 | |
| Yoav Doppelt | Tower Semiconductor | 46 | |
| Avraham Asheri | Elbit Systems | 77 | |
| Haim Levy | Bank Leumi Le Israel | 77 | |
| Amnon Dick | Bezeq Israeli Telecommunication | 64 | |
| Yael Andorn | El Al Israel | 47 | |
Management Performance
| Return On Equity | -0.24 | |||
| Return On Asset | 0.0363 |
Teva Pharmaceutical Leadership Team
Elected by the shareholders, the Teva Pharmaceutical's board of directors comprises two types of representatives: Teva Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Teva. The board's role is to monitor Teva Pharmaceutical's management team and ensure that shareholders' interests are well served. Teva Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Teva Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Moshe Many, Independent Director | ||
| Richard Daniell, Executive Vice President - European Commercial | ||
| Mark Sabag, Executive Vice President, Chief Human Resources Officer and Global Communications and Brand | ||
| Ronit SatchiFainaro, Independent Director | ||
| Richard Lerner, Independent Director | ||
| Galia Maor, Independent Director | ||
| Janet Vergis, Independent Director | ||
| Carlo Notaristefani, CEO of Global Operations and President of Global Operations | ||
| JeanMichel Halfon, Statutory - independent director | ||
| Eli Shani, Ex Portfolio | ||
| Dipankar Bhattacharjee, Senior Vice President CFO Americas and Head of Finance Operations | ||
| Abbas Hussain, Independent Director | ||
| Yitzhak Peterburg, Director | ||
| Hafrun Fridriksdottir, Executive Vice President and Presidentident of Global Generics R&D | ||
| Perry Nisen, Independent Director | ||
| Isaac Abravanel, Group Executive Vice President Teva Corporate in Israel and Global Community Alliances, Director | ||
| David Stark, Executive Vice President, Chief Legal Officer | ||
| Amir Elstein, Vice Chairman of the Board | ||
| Dan Suesskind, Director | ||
| Arie Belldegrun, Independent Director | ||
| Richard Egosi, Chief Legal Officer and Group Executive VP | ||
| Andrew Weil, Chief Accounting Officer | ||
| Jean Halfon, Statutory - independent director | ||
| Sven Dethlefs, Executive Vice President - Global Marketing & Portfolio | ||
| Robert Koremans, President CEO-Global Specialty Medicines | ||
| Gerald Lieberman, Independent Director | ||
| Roberto Mignone, Independent Director | ||
| Rosemary Crane, Independent Director | ||
| Nechemia Peres, Independent Director | ||
| Roger Abravanel, Independent Director | ||
| Eyal Desheh, CFO and Group Executive VP | ||
| Gianfranco Nazzi, Executive Vice President - International Markets Commercial | ||
| Kare Schultz, CEO Pres | ||
| Iris BeckCodner, Group Executive Vice President - Corporate Marketing Excellence and Communication | ||
| Amir Weiss, VP Officer | ||
| Brendan OGrady, Executive Vice President - North America Commercial | ||
| Michael Hayden, President - Global Research and Development, Chief Scientific Officer | ||
| Gabrielle Sulzberger, Statutory Independent Director | ||
| Eric Drape, Executive Vice President - Global Operations | ||
| Erez Vigodman, CEO and President Director and Member of Fin. and Invesment Committee | ||
| Eliyahu Kalif, Chief Financial Officer, Executive Vice President, Director | ||
| Kathleen Veit, Global VP | ||
| Joseph Nitzani, Independent Director | ||
| Deborah Griffin, Chief Accounting Officer | ||
| Timothy Wright, Head - Business Development, Strategy and Innovation | ||
| Sigurdur Olafsson, President and CEO - Global Generic Medicines Group | ||
| Murray Goldberg, Independent Director | ||
| Dan Propper, Independent Director | ||
| Ory Slonim, Independent Director | ||
| Michael McClellan, Chief Financial Officer, Executive Vice President | ||
| Kevin Mannix, Vice President Head of Investor Relations | ||
| Kaare Schultz, President, Chief Executive Officer, Director | ||
| Sol Barer, Independent Chairman of the Board | ||
| Eli Kalif, Chief Financial Officer, Executive Vice President, Director |
Teva Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Teva Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.24 | |||
| Return On Asset | 0.0363 | |||
| Profit Margin | (0.16) % | |||
| Operating Margin | 0.18 % | |||
| Current Valuation | 102.13 B | |||
| Shares Outstanding | 1.11 B | |||
| Shares Owned By Insiders | 0.77 % | |||
| Shares Owned By Institutions | 5.30 % | |||
| Price To Book | 1.18 X | |||
| Price To Sales | 2.32 X |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Teva Pharmaceutical Industries. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Complementary Tools for Teva Stock analysis
When running Teva Pharmaceutical's price analysis, check to measure Teva Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Teva Pharmaceutical is operating at the current time. Most of Teva Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Teva Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Teva Pharmaceutical's price. Additionally, you may evaluate how the addition of Teva Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |